Variable | All Patients (n = 2751) | Patients w Inactive Disease (n = 1249) | Patients w Active Disease (n = 1428) |
---|---|---|---|
SOCIODEMOGRAPHIC | |||
 Age (years) | 12.4 (4.7) | 11.8 (4.8) | 12.9 (4.6) |
 Female | 1675/2356 (71%) | 723/1024 (71%) | 929/1304 (71%) |
 Race (White) | 1885/2207 (85%) | 824/970 (85%) | 1045/1216 (86%) |
 Insurance Status (Private) | 1536/1769 (87%) | 713/812 (88%) | 814/946 (86%) |
CLINICAL CHARACTERISTICS | |||
 Disease Duration (months) | 68.1 (49.1) | 69.0 (48.4) | 67.2 (49.4) |
 ILAR Subtype | |||
  Polyarticular, RF (-) | 790 (29%) | 350 (28%) | 420 (29%) |
  Oligoarticular, persistent | 768 (28%) | 417 (33%) | 330 (23%) |
  Enthesitis related arthritis | 332 (12%) | 115 (9%) | 207 (14%) |
  Oligoarticular, extended | 286 (10%) | 138 (11%) | 136 (10%) |
  Psoriatic arthritis | 184 (7%) | 61 (5%) | 121 (8%) |
  Systemic arthritis | 174 (6%) | 87 (7%) | 83 (6%) |
  Polyarticular, RF (+) | 157 (6%) | 55 (4%) | 100 (7%) |
  Undifferentiated | 54 (2%) | 25 (2%) | 27 (2%) |
  ANA Positive | 1339 (49%) | 611 (49%) | 691 (49%) |
DISEASE ACTIVITY MEASURES | |||
 Active Uveitis | 133/2393 (6%) | 0 | 129/1286 (10%) |
 Systemic Features | 21 (<1%) | 0 | 21 (1%) |
 Morning Stiffness > 15 min | 1934/2389 (81%) | 0 | 452/1303 (35%) |
 Elevated ESR / CRP | 204 (7%) / 139 (5%) | 0 | 204 (14%) / 139 (10%) |
 Active Joint Count | 0.9 (2.0) | 0 | 1.8 (2.5) |
 MD Global Assessment | 1.0 (1.4) | 0.03 (0.1) | 1.8 (1.5) |
PATIENT-REPORTED MEASURES | |||
 Patient Global Assessment (0-10) | 1.7 (2.3) | 0.74 (1.5) | 2.6 (2.5) |
 Pain Score (0-10) | 2 (2.5) | 0.8 (1.5) | 2.9 (2.8) |
 CHAQ | 0.24 (0.44) | 0.11 (0.26) | 0.36 (0.52) |
MEDICATIONS | |||
 Non-biologic DMARDs | 1059 (38%) | 399 (32%) | 640 (45%) |
  Methotrexate | 914 (86%) | 350 (88%) | 549 (86%) |
  Leflunomide | 68 (6%) | 24 (6%) | 43 (7%) |
  Sulfasalazine | 51 (5%) | 16 (4%) | 34 (5%) |
  Hydroxychloroquine | 43 (4%) | 7 (2%) | 34 (5%) |
  Other | 14 (1%) | 5 (1%) | 10 (2%) |
  More than one | 33 (3%) | 3 (<1%) | 30 (5%) |
 Biologic DMARDs | 1101 (40%) | 434 (35%) | 684 (48%) |
  All Anti-TNF | 863 (31%) | 350 (28%) | 498 (35%) |
   Etanercept | 420 (38%) | 191 (44%) | 223 (33%) |
   Adalimumab | 331 (30%) | 125 (29%) | 202 (30%) |
   Infliximab | 105 (10%) | 32 (7%) | 68 (10%) |
   Certolizumab | 9 (<1%) | 5 (1%) | 4 (<1%) |
   Golimumab | 8 (<1%) | 3 (<1%) | 5 (<1%) |
  Tocilizumab | 97 (9%) | 32 (7%) | 64 (9%) |
  Abatacept | 80 (7%) | 20 (5%) | 60 (9%) |
  Anakinra | 23 (2%) | 13 (3%) | 9 (1%) |
  Canakinumab | 21 (2%) | 12 (3%) | 8 (1%) |
  Rituximab | 6 (<1%) | 1 (<1%) | 4 (<1%) |
  Tofacitinib | 4 (<1%) | 0 | 4 (<1%) |
  Other | 2 (<1%) | 2 (<1%) | 0 |
  More than one | 5 (<1%) | 2 (<1%) | 3 (<1%) |
 NSAIDs | |||
 Daily | 770 (28%) | 204 (16%) | 551 (29%) |
  Intermittent | 345 (13%) | 150 (12%) | 195 (14%) |
 Glucocorticoids | |||
  Intra-articular | 201 (7%) | 46 (4%) | 147 (10%) |
  Systemic | 84 (3%) | 17 (1%) | 63 (4%) |
  Ophthalmic | 119 (4%) | 19 (2%) | 94 (7%) |